Biogen has received a clutch of useful data from the initially disappointing SYNERGY trial, and is now evaluating the design of further possible Phase II clinical studies of opicinumab, a potential myelin repair agent for the treatment of multiple sclerosis.
“What was important about the study was that we were trying to identify, for the first time, patients who might benefit from a remyelination strategy,” said Biogen researcher Diego Cadavid during the annual meeting of the European Committee for Treatment
